HeimAIM • NYSEAMERICAN
add
AIM ImmunoTech Inc
Við síðustu lokun
8,80 $
Dagbil
8,85 $ - 9,51 $
Árabil
2,51 $ - 14,93 $
Markaðsvirði
6,76 m. USD
Meðalmagn
10,08 þ.
V/H-hlutf.
-
A/V-hlutfall
-
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | mar. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 16,00 þ. | -60,00% |
Rekstrarkostnaður | 3,62 m. | -37,13% |
Nettótekjur | -3,70 m. | 36,31% |
Hagnaðarhlutfall | -23,16 þ. | -59,23% |
Hagnaður á hvern hlut | -5,00 | 58,33% |
EBITDA | -3,56 m. | 37,26% |
Virkt skatthlutfall | — | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | mar. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 2,25 m. | -79,46% |
Heildareignir | 6,25 m. | -61,41% |
Heildarskuldir | 10,10 m. | -11,07% |
Eigið fé alls | -3,86 m. | — |
Útistandandi hlutabréf | 764,24 þ. | — |
Eiginfjárgengi | -1,65 | — |
Arðsemi eigna | -121,80% | — |
Ávöxtun eigin fjár | -6.371,48% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | mar. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | -3,70 m. | 36,31% |
Handbært fé frá rekstri | -2,36 m. | 50,97% |
Reiðufé frá fjárfestingum | 898,00 þ. | 668,35% |
Reiðufé frá fjármögnun | 660,00 þ. | -76,67% |
Breyting á handbæru fé | -803,00 þ. | 62,55% |
Frjálst peningaflæði | -1,76 m. | 36,37% |
Um
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
Stofnsett
1966
Höfuðstöðvar
Vefsvæði
Starfsfólk
22
